High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E

World Journal of Microbiology and Biotechnology

Volumn 30, Issue 6, 2014, Pages 1861-1867

  Valipour, Ebrahim ^a   Moosavi, Mir Latif ^b   Amani, Jafar ^b   Nazarian, Shahram ^b  

^a University of Cukuruva   (Turkey)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

Binding domain; BoNT E; Synthetic gene; Western blot

Indexed keywords

ESCHERICHIA COLI; GENE ENCODING; MAMMALS; RECOMBINANT PROTEINS;

BACTERIAL CULTURES; BINDING DOMAIN; BONT/E; BOTULINUM NEUROTOXINS; FULLY PROTECTED; HIGH LEVEL EXPRESSION; SYNTHETIC GENES; WESTERN BLOTS;

PURIFICATION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS;

BACTERIAL VACCINE; BOTULINUM TOXIN; BOTULINUM TOXIN E; RECOMBINANT PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; BOTULISM; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MOUSE; PHYSIOLOGY;

ANIMALS; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS;

EID: 84900856706     PISSN: 09593993     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11274-014-1609-0     Document Type: Article

References (35)

1. Agarwal R, Eswaramoorthy S, Kumaran D et al (2004) Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain. Protein Expr Purif 34: 95-102.
2. Arimitsu H, Lee JC, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H et al (2004) Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum type C and D neurotoxins. Clin Diagn Lab Immunol 11: 496-502.
3. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76: 1314-1318.
4. Basiri M, Mousavi SL, Basiri H, Rasooli I (2010) An epitopic approach to designing and characterization of a multiple antigenic polypeptide against botulinum neurotoxins A and E. World J Microbiol Biotechnol 26: 1659-1666.
5. Binz T, Rummel A (2009) Cell entry strategy of clostridial neurotoxins. J Neurochem 109: 1584-1595.
6. Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P, Smith L, LeClaire RD (2006) Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47: 877-884.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
8. Byrne MP, Smith LA (2000) Development of vaccines for prevention of botulism. Biochimie 82: 955-966.
9. Chen S, Kim JJ, Barbieri JT (2007) Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem 282: 9621-9627.
10. Christina LP, William HT, Marite B et al (2008) Recombinant holotoxoid vaccine against botulism. Infect Immun 76(1): 437-442.
11. Dressler D, Adib SF (2005) Botulinum toxin: mechanisms of action. Eur Neurol 53: 3-9.
12. Dulal S, Ban B, Yang GH, Jung HH (2012) Cloning, expression, purification, and characterization of Clostridium botulinum neurotoxin serotype F domains. Nepal J Biotechnol 2(1): 1-15.
13. Hamidi B, Ebrahimi F, Abbas Hajizadeh A, Keshavarz AH (2012) Fusion and cloning of the binding domains of botulinum neurotoxin type A and B in E. coli DH5α. Eur J Exp Biol 2(4): 1154-1160.
14. Hill KK, Smith TJ, Helma CH, Ticknor LO (2007) Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 189(3): 818-832.
15. Holley JL, Elmore M, Mauchline M, Minton N, Titball RW (2000) Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 19: 288-297.
16. Jensen MJ, Smith TJ, Ahmed SA, Smith LA (2003) Expression, purification, and characterization of the botulinum neurotoxin A catalytic domain and its C-terminal fusion variants. Toxicon 41: 670-691.
17. Karlin S, Mrazek J, Campbell AM (1998) Codon usages in different gene classes of the Escherichia coli genome. Mol Microbiol 29: 1341-1355.
18. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, Schiavo G (1999) Functional characterization of tetanus and botulinum neurotoxins binding domain. J Cell Sci 112: 2715-2724.
19. LaPenotiere HF, Clayton MA, Middlebrook JL (1995) Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon 33: 1383-1386.
20. Li L, Singh BR (1999) Structure-function relationship of clostridial neurotoxins. J Toxicol Toxin Rev 18: 95-112.
21. Makoff AJ, Oxer MD, Romanos MA, Fairweather NF, Ballantine S (1989) Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic Acids Res 17: 10191-10202.
22. Mansour AA, Mousavi SL, Rasooli I, Nazarian S, Amani J, Farhadi N (2010) Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E. Biologicals 38: 260-264.
23. Minaei ME (2002) production and purification of botulinum neurotoxin type E and preparation of antibody against the toxin. Dissertation, University of Imam Hosein, Tehran, Iran.
24. Modarres SH, Vahdani P (2001) Epidemiologic study and determination of botulism causative types of Clostridium botulinum strains in Iran. In: Fourth congress of infectious diseases in Iran, pp 411-412.
25. Mousavi ML, Montaser Kouhsari S, Nazarian S, Rasooli I, Amani J (2004) Cloning, expression and purification of Clostridium botulinum neurotoxin type E binding domain. Iran J Biotechnol 2: 183-188.
26. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75: 3043-3054.
27. Rusnak JM, Smith LA (2009) Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin 5: 794-805.
28. Sambrook J, Fritsch EF, Maniatis T (2001) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
29. Smith LA (1998) Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36: 1539-1548.
30. Thanongsaksrikul J, Chaicumpa W (2011) Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins 3: 469-488.
31. Woodward LA, Arimitsu H, Hirst R, Oguma K (2003) Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 71: 2941-2944.
32. Yu YZ, Sun ZW, Wang S, Yu WY (2007) High-level expression of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Sheng Wu Gong Cheng Xue Bao 23: 812-817.
33. Zdanovsky AG, Zdanovskaia MV (2000) Simple and efficient method for heterologous expression of clostridial proteins. Appl Environ Microbiol 66(8): 3166-3173.
34. Zhao H, Nakamura K, Kohda T, Mukamoto M, Kozaki S (2012) Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Jpn J Infect Dis 65: 138-145.
35. Zhou Y, Singh BR (2004) Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 34: 8-16.